Showing results (71-80 of 723) with videos related to
Sort By:
Pageof 73
The Journal of Nutrition|February 1, 2013
Supplementation with n3 fatty acid ethyl esters increases large and small artery elasticity in obese adults on a weight loss dietAnnette T Y Wong, Dick C Chan, P Hugh R Barrett, et al.Journal of Internal Medicine|February 3, 2022
PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual mechanism of action in statin-treated patients with very high apolipoprotein(a) concentrationQidi Ying, Dick C Chan, Jing Pang, et al.Obesity Research|January 17, 2003
Fat compartments and apolipoprotein B-100 kinetics in overweight-obese menGerald F Watts, Dick C Chan, P Hugh R Barrett, et al.Clinical Chemistry|July 17, 2019
Effect of Lipoprotein(a) on the Diagnosis of Familial Hypercholesterolemia: Does It Make a Difference in the Clinic?Dick C Chan, Jing Pang, Amanda J Hooper, et al.Clinical Cardiology|May 6, 2021
Effectiveness of proprotein convertase subtilisin/kexin-9 monoclonal antibody treatment on plasma lipoprotein(a) concentrations in patients with elevated lipoprotein(a) attending a clinicAnindita Chakraborty, Jing Pang, Dick C Chan, et al.The Journal of Clinical Endocrinology and Metabolism|March 11, 2014
Effect of ω-3 fatty acid ethyl esters on apolipoprotein B-48 kinetics in obese subjects on a weight-loss diet: a new tracer kinetic study in the postprandial stateAnnette T Y Wong, Dick C Chan, P Hugh R Barrett, et al.Diabetes Care|February 27, 2010
Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss dietDick C Chan, Gerald F Watts, Seng Khee Gan, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|June 9, 2018
Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein MetabolismDick C Chan, Gerald F Watts, Ransi Somaratne, et al.Diabetes Care|August 10, 2007
Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levelsTheodore W K Ng, Gerald F Watts, P Hugh R Barrett, et al.The Journal of Clinical Endocrinology and Metabolism|August 6, 2011
Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesityEsther M M Ooi, Gerald F Watts, Dennis L Sprecher, et al.Pageof 73